Featured Publications
Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosis
2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.Peer-Reviewed Original ResearchConceptsPD-L1 blockadePD-1 blockadeAsymptomatic multiple myelomaMonocyte-derived DCsPD-L1Immunologic effectsT cellsMyeloid cellsAntigen-specific T cell expansionAnti-PD-1 therapyMyeloid antigen-presenting cellsDistinct inflammatory signatureSystemic immunologic effectsLung cancer patientsT cell expansionAntigen-presenting cellsMyeloid activationMyeloid inflammationInflammatory signatureNIH/NCICheckpoint blockadeDC maturationL1 therapyCombination therapyInflammatory phenotype
2013
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaAggressive B-cell lymphomasB-cell lymphomaPosttransplant lymphoproliferative disorderClassical Hodgkin lymphomaLarge B-cell lymphomaPD-L1Hodgkin's lymphomaT-cell/histiocyte-rich B-cell lymphomaExtranodal NK/T-cell lymphomaTissue biopsiesEBV-positive posttransplant lymphoproliferative disordersHistiocyte-rich B-cell lymphomaPD-1/PD-L1 pathwayNK/T-cell lymphomaPD-1/PD-L1Primary mediastinal large B-cell lymphomaNodular lymphocyte predominant Hodgkin lymphomaMixed cellularity classical Hodgkin lymphomaMediastinal large B-cell lymphomaCell death ligand 1Lymphocyte predominant Hodgkin lymphomaPD-L1 protein expressionPD-L1 expressionPD-L1 pathway